Finland - finsk - Fimea (Suomen lääkevirasto)

medical valley invest ab - metformin hydrochloride - depottabletti - 1000 mg - metformiini

Finland - finsk - Fimea (Suomen lääkevirasto)

medical valley invest ab - metformin hydrochloride - depottabletti - 750 mg - metformiini

Finland - finsk - Fimea (Suomen lääkevirasto)

medical valley invest ab - metformin hydrochloride - depottabletti - 500 mg - metformiini

Den Europæiske Union - finsk - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Den Europæiske Union - finsk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Finland - finsk - Fimea (Suomen lääkevirasto)

orion corporation - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini

Finland - finsk - Fimea (Suomen lääkevirasto)

orion corporation - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini

Finland - finsk - Fimea (Suomen lääkevirasto)

orion corporation - metformini hydrochloridum - depottabletti - 500 mg - metformiini

Finland - finsk - Fimea (Suomen lääkevirasto)

orion corporation - metformini hydrochloridum - depottabletti - 750 mg - metformiini

Finland - finsk - Fimea (Suomen lääkevirasto)

orion corporation - metformini hydrochloridum - depottabletti - 1000 mg - metformiini